Inflammation-mediating proteases: Structure, function in (Patho) physiology and inhibition

Protein and Peptide Letters

Volumn 21, Issue 12, 2014, Pages 1209-1229

  Manček Keber, Mateja ^a,b  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b EN FIST Centre of Excellence   (Slovenia)

Author keywords

(Patho)physiology; ADAMTS; Granzymes; Inflammation; Inhibitors; Kallikreins; Plasmin; Proteases

Indexed keywords

ADAMTS1 PROTEIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; ALTEPLASE; AMINOCAPROIC ACID; APROTININ; ECALLANTIDE; GLUCOCORTICOID; GRANZYME; GRANZYME A; GRANZYME B; KALLIKREIN; KALLISTATIN; OCRIPLASMIN; PLASMIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PREDNISOLONE; PROTEASE INHIBITOR 9; PROTEIN ADAMTS; PROTEINASE; PROTEINASE INHIBITOR; RETEPLASE; TENECTEPLASE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; UPAMOSTAT; PEPTIDE HYDROLASE;

ADVANCED CANCER; ALZHEIMER DISEASE; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CANCER GROWTH; CARDIOVASCULAR DISEASE; CONJUNCTIVITIS; DRUG APPROVAL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBSTRATE; GRAFT REJECTION; HEART INFARCTION; HUMAN; INFLAMMATION; LIGNEOUS CONJUNCTIVITIS; LUNG EMBOLISM; MENORRHAGIA; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PROSTATE CANCER; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE; ANIMAL; DISEASES; ENZYMOLOGY; METABOLISM; MOUSE;

ANIMALS; DISEASE; HUMANS; INFLAMMATION; MICE; PEPTIDE HYDROLASES; PROTEASE INHIBITORS;

EID: 84925666462     PISSN: 09298665     EISSN: 18755305     Source Type: Journal    
DOI: None     Document Type: Article

References (358)

1. Puente, X. S.; Sanchez, L. M.; Overall, C. M.; Lopez-Otin, C. Human and mouse proteases: A comparative genomic approach. Nat. Rev. Genet., 2003, 4(7), 544-558.
2. Iyer, R. P.; Patterson, N. L.; Fields, G. B.; Lindsey, M. L. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am. J. Physiol.-Heart Circul. Physiol., 2012, 303(8), H919-H930.
3. Moss, L. A. S.; Jensen-Taubman, S.; Stetler-Stevenson, W. G. Matrix Metalloproteinases Changing Roles in Tumor Progression and Metastasis. Am. J. Pathol., 2012, 181(6), 1895-1899.
4. Knapinska, A.; Fields, G. B. Chemical Biology for Understanding Matrix Metalloproteinase Function. ChemBioChem, 2012, 13(14), 2002-2020.
5. Stanton, H.; Melrose, J.; Little, C. B.; Fosang, A. J. Proteoglycan degradation by the ADAMTS family of proteinases. Biochim. Biophys. Acta-Mol. Basis Dis., 2011, 1812(12), 1616-1629.
6. Kuno, K.; Iizasa, H.; Ohno, S.; Matsushima, K. The exon/intron organization and chromosomal mapping of the mouse ADAMTS-1 gene encoding an ADAM family protein with TSP motifs. Genomics, 1997, 46(3), 466-471.
7. Kuno, K.; Matsushima, K. ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region. J. Biol. Chem., 1998, 273(22), 13912-13917.
8. Vanwart, H. E.; Birkedalhansen, H. The Cysteine Switch - a Principle of Regulation of Metalloproteinase Activity with Potential Applicability to the Entire Matrix Metalloproteinase Gene Family. Proc. Natl. Acad. Sci. USA, 1990, 87(14), 5578-5582.
9. Wang, P.; Tortorella, M.; England, K.; Malfait, A. M.; Thomas, G.; Arner, E. C.; Pei, D. Q. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (aggrecanase-1) in the trans-Golgi network. J. Biol. Chem., 2004, 279(15), 15434-15440.
10. Malfait, A. M.; Arner, E. C.; Song, R. H.; Alston, J. T.; Markosyan, S.; Staten, N.; Yang, Z.; Griggs, D. W.; Tortorella, M. D. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch. Biochem. Biophys., 2008, 478(1), 43-51.
11. Gerhardt, S.; Hassall, G.; Hawtin, P.; McCall, E.; Flavell, L.; Minshull, C.; Hargreaves, D.; Ting, A.; Pauptit, R. A.; Parker, A. E.; Abbott, W. M. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J. Mol. Biol., 2007, 373(4), 891-902.
12. Mosyak, L.; Georgiadis, K.; Shane, T.; Svenson, K.; Hebert, T.; McDonagh, T.; Mackie, S.; Olland, S.; Lin, L.; Zhong, X.; Kriz, R.; Reifenberg, E. L.; Collins-Racie, L. A.; Corcoran, C.; Freeman, B.; Zollner, R.; Marvell, T.; Vera, M.; Sum, P. E.; Lavallie, E. R.; Stahl, M.; Somers, W. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci., 2008, 17(1), 16-21.
13. Shieh, H. S.; Mathis, K. J.; Williams, J. M.; Hills, R. L.; Wiese, J. F.; Benson, T. E.; Kiefer, J. R.; Marino, M. H.; Carroll, J. N.; Leone, J. W.; Malfait, A. M.; Arner, E. C.; Tortorella, M. D.; Tomasselli, A. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J. Biol. Chem., 2008, 283(3), 1501-1507.
14. Kuno, K.; Terashima, Y.; Matsushima, K. ADAMTS-1 is an active metalloproteinase associated extracellular matrix. J. Biol. Chem., 1999, 274(26), 18821-18826.
15. Tortorella, M. D.; Burn, T. C.; Pratta, M. A.; Abbaszade, I.; Hollis, J. M.; Liu, R.; Rosenfeld, S. A.; Copeland, R. A.; Decicco, C. P.; Wynn, R.; Rockwell, A.; Yang, F.; Duke, J. L.; Solomon, K.; George, H.; Bruckner, R.; Nagase, H.; Itoh, Y.; Ellis, D. M.; Ross, H.; Wiswall, B. H.; Murphy, K.; Hillman, M. C.; Hollis, G. F.; Newton, R. C.; Magolda, R. L.; Trzaskos, J. M.; Arner, E. C. Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins. Science, 1999, 284(5420), 1664-1666.
16. Sandy, J. D.; Flannery, C. R.; Neame, P. J.; Lohmander, L. S. The Structure of Aggrecan Fragments in Human Synovial-Fluid - Evidence for the Involvement in Osteoarthritis of a Novel Proteinase Which Cleaves the Glu-373-Ala-374 Bond of the Interglobular Domain. J. Clin. Invest., 1992, 89(5), 1512-1516.
17. Lohmander, L. S.; Neame, P. J.; Sandy, J. D. The Structure of Aggrecan Fragments in Human Synovial-Fluid - Evidence That Aggrecanase Mediates Cartilage Degradation in Inflammatory Joint Disease, Joint Injury, and Osteoarthritis. Arthritis Rheum., 1993, 36(9), 1214-1222.
18. Tortorella, M. D.; Liu, R. Q.; Burn, T.; Newton, R. C.; Arner, E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol., 2002, 21(6), 499-511.
19. Arner, E. C. Aggrecanase-mediated cartilage degradation. Curr. Opin. Pharmacol., 2002, 2(3), 322-329.
20. Kuno, K.; Bannai, K.; Hakozaki, M.; Matsushima, K.; Hirose, K. The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem. Biophys. Res. Commun., 2004, 319(4), 1327-1333.
21. Rocks, N.; Paulissen, G.; Calvo, F. Q.; Polette, M.; Gueders, M.; Munaut, C.; Foidart, J. M.; Noel, A.; Birembaut, P.; Cataldo, D. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br. J. Cancer, 2006, 94(5), 724-730.
22. Minobe, K.; Ono, R.; Matsumine, A.; Shibata-Minoshima, F.; Izawa, K.; Oki, T.; Kitaura, J.; Iino, T.; Takita, J.; Iwamoto, S.; Hori, H.; Komada, Y.; Uchida, A.; Hayashi, Y.; Kitamura, T.; Nosaka, T. Expression of ADAMTS4 in Ewing's sarcoma. Int. J. Oncol., 2010, 37(3), 569-581.
23. Cal, S.; Arguelles, J. M.; Fernandez, P. L.; Lopez-Otin, C. Identification, characterization, and intracellular processing of ADAM-TS12, a novel human disintegrin with a complex structural organization involving multiple thrombospondin-1 repeats. J. Biol. Chem., 2001, 276(21), 17932-17940.
24. Jonnsson-Rylander, A. C.; Nilsson, T.; Fritsche-Danielson, R.; Hammarstrom, A.; Behrendt, M.; Andersson, J. O.; Lindgren, K.; Andersson, A. K.; Wallbrandt, P.; Rosengren, B.; Brodin, P.; Thelin, A.; Westin, A.; Hurt-Camejo, E.; Lee-Sogaard, C. H. Role of ADAMTS-1 in atherosclerosis - Remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler. Thromb. Vasc. Biol., 2005, 25(1), 180-185.
25. Wagsater, D.; Bjork, H.; Zhu, C. Y.; Bjorkegren, J.; Valen, G.; Hamsten, A.; Eriksson, P. ADAMTS-4 and-8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis, 2008, 196(2), 514-522.
26. Sabatine, M. S.; Ploughman, L.; Simonsen, K. L.; Iakoubova, O. A.; Kirchgessner, T. G.; Ranade, K.; Tsuchihashi, Z.; Zerba, K. E.; Long, D. U.; Tong, C. H.; Packard, C. J.; Pfeffer, M. A.; Devlin, J. J.; Shepherd, J.; Campos, H.; Sacks, F. M.; Braunwald, E. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler. Thromb. Vasc. Biol., 2008, 28(3), 562-567.
27. Little, C. B.; Mittaz, L.; Belluoccio, D.; Rogerson, F. M.; Campbell, I. K.; Meeker, C. T.; Bateman, J. F.; Pritchard, M. A.; Fosang, A. J. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum., 2005, 52(5), 1461-1472.
28. Hofer, T. P. J.; Frankenberger, M.; Mages, J.; Lang, R.; Hoffmann, R.; Colige, A.; Ziegler-Heitbrock, L. Tissue-specific induction of ADAMTS2 in monocytes and macrophages by glucocorticoids. J. Mol. Med., 2008, 86(3), 323-332.
29. Tortorella, M. D.; Malfait, A. M.; Deccico, C.; Arner, E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage, 2001, 9(6), 539-552.
30. Stanton, H.; Rogerson, F. M.; East, C. J.; Golub, S. B.; Lawlor, K. E.; Meeker, C. T.; Little, C. B.; Last, K.; Farmer, P. J.; Campbell, I. K.; Fourie, A. M.; Fosang, A. J. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature, 2005, 434(7033), 648-652.
31. Botter, S. M.; Glasson, S. S.; Hopkins, B.; Clockaerts, S.; Weinans, H.; van Leeuwen, J.; Osch, G. ADAMTS5-/-mice have less subchondral bone changes after induction of osteoarthritis through surgical instability: implications for a link between cartilage and subchondral bone changes. Osteoarthritis Cartilage, 2009, 17(5), 636-645.
32. Didangelos, A.; Mayr, U.; Monaco, C.; Mayr, M. Novel Role of ADAMTS-5 Protein in Proteoglycan Turnover and Lipoprotein Retention in Atherosclerosis. J. Biol. Chem., 2012, 287(23), 19341-19345.
33. Goertsches, R.; Comabella, M.; Navarro, A.; Perkal, H.; Montalban, X. Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. J. Neuroimmunol., 2005, 164(1-2), 140-147.
34. Haddock, G.; Cross, A. K.; Plumb, J.; Surr, J.; Buttle, D. J.; Bunning, R. A. D.; Woodroofe, M. N. Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult. Scler., 2006, 12(4), 386-396.
35. Levy, G. G.; Nichols, W. C.; Lian, E. C.; Foroud, T.; McClintick, J. N.; McGee, B. M.; Yang, A. Y.; Siemieniak, D. R.; Stark, K. R.; Gruppo, R.; Sarode, R.; Shurin, S. B.; Chandrasekaran, V.; Stabler, S. P.; Sabio, H.; Bouhassira, E. E.; Upshaw, J. D.; Ginsburg, D.; Tsai, H. M. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001, 413, (6855), 488-494.
36. Satoh, K.; Suzuki, N.; Yokota, H. ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs) is transcriptionally induced in beta-amyloid treated rat astrocytes. Neurosci. Lett., 2000, 289(3), 177-180.
37. Pratta, M. A.; Scherle, P. A.; Yang, G. J.; Liu, R. Q.; Newton, R. C. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum., 2003, 48(1), 119-133.
38. Sasaki, M.; Seo-Kiryu, S.; Kato, R.; Kita, S.; Kiyama, H. A disintegrin and metalloprotease with thrombospondin type1 motifs (ADAMTS-1) and IL-1 receptor type 1 mRNAs are simultaneously induced in nerve injured motor neurons. Mol. Brain Res., 2001, 89(1-2), 158-163.
39. Vankemmelbeke, M. N.; Holen, I.; Wilson, A. G.; Ilic, M. Z.; Handley, C. J.; Kelner, G. S.; Clark, M.; Liu, C. L.; Maki, R. A.; Burnett, D.; Buttle, D. J. Expression and activity of ADAMTS-5 in synovium. Eur. J. Biochem., 2001, 268(5), 1259-1268.
40. Wachsmuth, L.; Bau, B.; Fan, Z. Y.; Pecht, A.; Gerwin, N.; Aigner, T. ADAMTS-1, a gene product of articular chondrocytes in vivo and in vitro, is downregulated by interleukin 1 beta. J. Rheumatol., 2004, 31(2), 315-320.
41. Norata, G. D.; Bjork, H.; Hamsten, A.; Catapano, A. L.; Eriksson, P. High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factoralpha in human endothelial cells. Matrix Biol., 2004, 22(7), 557-560.
42. Mimata, Y.; Kamataki, A.; Oikawa, S.; Murakami, K.; Uzuki, M.; Shimamura, T.; Sawai, T. Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int. J. Rheum. Dis., 2012, 15(1), 36-44.
43. Garcia-Faroldi, G.; Ronnberg, E.; Orro, A.; Calounova, G.; Guss, B.; Lundequist, A.; Pejler, G. ADAMTS: Novel proteases expressed by activated mast cells. Biol. Chem., 2013, 394(2), 291-305.
44. Moncada-Pazos, A.; Obaya, A. J.; Llamazares, M.; Heljasvaara, R.; Suarez, M. F.; Colado, E.; Noel, A.; Cal, S.; Lopez-Otin, C. ADAMTS-12 Metalloprotease Is Necessary for Normal Inflammatory Response. J. Biol. Chem., 2012, 287(47), 39554-63.
45. Roos, M. A.; Gennero, L.; Denysenko, T.; Reguzzi, S.; Cavallo, G.; Pescarmona, G. P.; Ponzetto, A. Microparticles in physiological and in pathological conditions. Cell Biochem. Funct., 2010, 28(7), 539-548.
46. Lo Cicero, A.; Majkowska, I.; Nagase, H.; Di Liegro, I.; Troeberg, L. Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biol., 2012, 31(4), 229-233.
47. Tortorella, M. D.; Malfait, F.; Barve, R. A.; Shieh, H. S.; Malfait, A. M. A Review of the ADAMTS Family, Pharmaceutical Targets of the Future. Curr. Pharm. Design, 2009, 15(20), 2359-2374.
48. Kashiwagi, M.; Tortorella, M.; Nagase, H.; Brew, K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem., 2001, 276(16), 12501-12504.
49. Rodriguez-Manzaneque, J. C.; Westling, J.; Thai, S. N. M.; Luque, A.; Knauper, V.; Murphy, G.; Sandy, J. D.; Iruela-Arispe, M. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem. Biophys. Res. Commun., 2002, 293(1), 501-508.
50. Lim, N. H.; Kashiwagi, M.; Visse, R.; Jones, J.; Enghild, J. J.; Brew, K.; Nagase, H. Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications. Biochem. J., 2010, 431, 113-122.
51. Tortorella, M. D.; Arner, E. C.; Hills, R.; Easton, A.; Korte-Sarfaty, J.; Fok, K.; Wittwer, A. J.; Liu, R. Q.; Malfait, A. M. alpha (2) - Macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J. Biol. Chem., 2004, 279(17), 17554-17561.
52. Munteanu, S. E.; Ilic, M. Z.; Handley, C. J. Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures. Matrix Biol., 2002, 21(5), 429-440.
53. Troeberg, L.; Fushimi, K.; Khokha, R.; Emonard, H.; Ghosh, P.; Nagase, H. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. Faseb J., 2008, 22(10), 3515-3524.
54. Jones, G. C. ADAMTS proteinases: Potential therapeutic targets? Curr. Pharm. Biotechnol., 2006, 7(1), 25-31.
55. De Rienzo, F.; Saxena, P.; Filomia, F.; Caselli, G.; Colace, F.; Stasi, L.; Giordani, A.; Menziani, M. C. Progress Towards the Identification of New Aggrecanase Inhibitors. Curr. Med. Chem., 2009, 16(19), 2395-2415.
56. Andreini, C.; Banci, L.; Bertini, I.; Elmi, S.; Rosato, A. Comparative analysis of the ADAM and ADAMTS families. J. Proteome Res., 2005, 4(3), 881-888.
57. Peng, J. H.; Gong, L. L.; Si, K.; Bai, X. Y.; Du, G. H. Fluorescence Resonance Energy Transfer Assay for High-Throughput Screening of ADAMTS1 Inhibitors. Molecules, 2011, 16(12), 10709-10721.
58. Filomia, F.; Saxena, P.; Durante, C.; de Rienzo, F.; Cocchi, M.; Menziani, M. C., Computational Insights into ADAMTS4, ADAMTS5 and MMP13 Inhibitor Selectivity. Mol. Inf., 2012, 31(6-7), 421-430.
59. Shiozaki, M.; Maeda, K.; Miura, T.; Kotoku, M.; Yamasaki, T.; Matsuda, I.; Aoki, K.; Yasue, K.; Imai, H.; Ubukata, M.; Suma, A.; Yokota, M.; Hotta, T.; Tanaka, M.; Hase, Y.; Haas, J.; Fryer, A. M.; Laird, E. R.; Littmann, N. M.; Andrews, S. W.; Josey, J. A.; Mimura, T.; Shinozaki, Y.; Yoshiuchi, H.; Inaba, T., Discovery of (1S, 2R, 3R)-2, 3-Dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: Novel and Highly Selective Aggrecanase Inhibitors. J. Med. Chem., 2011, 54(8), 2839-2863.
60. Vankemmelbeke, M. N.; Jones, G. C.; Fowles, C.; Ilic, M. Z.; Handley, C. J.; Day, A. J.; Knight, C. G.; Mort, J. S.; Buttle, D. J., Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur. J. Biochem., 2003, 270(11), 2394-2403.
61. Hatcher, V. B.; Oberman, M. S.; Lazarus, G. S.; Grayzel, A. I., Cytotoxic Proteinase Isolated from Human Lymphocytes. J. Immunol., 1977, 120(2), 665-670.
62. Pasternack, M. S.; Eisen, H. N., A Novel Serine Esterase Expressed by Cyto-Toxic Lymphocytes-T. Nature, 1985, 314(6013), 743-745.
63. Masson, D.; Nabholz, M.; Estrade, C.; Tschopp, J., Granules of Cytolytic Lymphocytes-T Contain 2 Serine Esterases. Embo J., 1986, 5(7), 1595-1600.
64. Young, J. D. E.; Leong, L. G.; Liu, C. C.; Damiano, A.; Wall, D. A.; Cohn, Z. A., Isolation and Characterization of a Serine Esterase from Cytolytic T-Cell Granules. Cell, 1986, 47(2), 183-194.
65. Estebanez-Perpina, E.; Fuentes-Prior, P.; Belorgey, D.; Braun, M.; Kiefersauer, R.; Maskos, K.; Huber, R.; Rubin, H.; Bode, W., Crystal structure of the caspase activator human granzyme B, a proteinase highly specific for an Asp-P1 residue. Biol. Chem., 2000, 381(12), 1203-1214.
66. Rotonda, J.; Garcia-Calvo, M.; Bull, H. G.; Geissler, W. M.; McKeever, B. M.; Willoughby, C. A.; Thornberry, N. A.; Becker, J. W., The three-dimensional structure of human granzyme B compared to caspase-3, key mediators of cell death with cleavage specificity for aspartic acid in P1. Chem. Biol., 2001, 8(4), 357-368.
67. Barkan, D. T.; Hostetter, D. R.; Mahrus, S.; Pieper, U.; Wells, J. A.; Craik, C. S.; Sali, A., Prediction of protease substrates using sequence and structure features. Bioinformatics, 2010, 26(14), 1714-1722.
68. Taub, D. D.; Sayers, T. J.; Carter, C. R. D.; Ortaldo, J. R., Alpha-Chemokine and Beta-Chemokine Induce Nk Cell-Migration and Enhance Nk-Mediated Cytolysis. J. Immunol., 1995, 155(8), 3877-3888.
69. Loetscher, P.; Seitz, M.; ClarkLewis, I.; Baggiolini, M.; Moser, B., Activation of NK cells by CC chemokines - Chemotaxis, Ca2+ mobilization, and enzyme release. J. Immunol., 1996, 156, (1), 322-327.
70. Pipkin, M. E.; Sacks, J. A.; Cruz-Guilloty, F.; Lichtenheld, M. G.; Bevan, M. J.; Rao, A., Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T Cells. Immunity, 2010, 32(1), 79-90.
71. Kagi, D.; Ledermann, B.; Burki, K.; Seiler, P.; Odermatt, B.; Olsen, K. J.; Podack, E. R.; Zinkernagel, R. M.; Hengartner, H., Cytotoxicity Mediated by T-Cells and Natural-Killer-Cells Is Greatly Impaired in Perforin Deficient Mice. Nature, 1994, 369(6475), 31-37.
72. Veugelers, K.; Motyka, B.; Frantz, C.; Shostak, I.; Sawchuk, T.; Bleackley, R. C., The granzyme B-serglycin complex from cytotoxic granules requires dynamin for endocytosis. Blood, 2004, 103, (10), 3845-3853.
73. Trapani, J. A.; Sutton, V. R.; Thia, K. Y. T.; Li, Y. Q.; Froelich, C. J.; Jans, D. A.; Sandrin, M. S.; Browne, K. A., A clathrin/dynamin- and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death. J. Cell Biol., 2003, 160(2), 223-233.
74. Li, P.; Zheng, G. Y.; Yang, Y.; Zhang, C. G.; Xiong, P.; Xu, Y.; Fang, M.; Tan, Z.; Zheng, F.; Gong, F. L., Granzyme B is recovered by natural killer cells via clathrin-dependent endocytosis. Cell. Mol. Life Sci., 2010, 67(18), 3197-3208.
75. Darmon, A. J.; Nicholson, D. W.; Bleackley, R. C. Activation of the Apoptotic Protease Cpp32 by Cytotoxic T-Cell-Derived Granzyme-B. Nature, 1995, 377, (6548), 446-448.
76. Adrain, C.; Murphy, B. M.; Martin, S. J. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biol. Chem., 2005, 280(6), 4663-4673.
77. Wang, S.; Xia, P.; Shi, L.; Fan, Z. FADD cleavage by NK cell granzyme M enhances its self-association to facilitate procaspase-8 recruitment for auto-processing leading to caspase cascade. Cell Death Differ., 2012, 19(4), 605-615.
78. Ida, H.; Nakashima, T.; Kedersha, N. L.; Yamasaki, S.; Huang, M.; Izumi, Y.; Miyashita, T.; Origuchi, T.; Kawakami, A.; Migita, K.; Bird, P. I.; Anderson, P.; Eguchi, K. Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur J Immunol, 2003, 33(12), 3284-3292.
79. Martinvalet, D.; Dykxhoorn, D. M.; Ferrini, R.; Lieberman, J. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell, 2008, 133, (4), 681-692.
80. Hostetter, D. R.; Loeb, C. R. K.; Chu, F.; Craik, C. S. Hip is a prosurvival substrate of granzyme B. J. Biol. Chem., 2007, 282(38), 27865-27874.
81. Hiebert, P. R.; Granville, D. J. Granzyme B in injury, inflammation, and repair. Trends Mol. Med, 2012, 18(12), 732-741.
82. Irmler, M.; Hertig, S.; Macdonald, H. R.; Sadoul, R.; Becherer, J. D.; Proudfoot, A.; Solari, R.; Tschopp, J. Granzyme-a Is an Interleukin-1-Beta-Converting Enzyme. J. Exp. Med., 1995, 181(5), 1917-1922.
83. Omoto, Y.; Yamanaka, K.; Tokime, K.; Kitano, S.; Kakeda, M.; Akeda, T.; Kurokawa, I.; Gabazza, E. C.; Tsutsui, H.; Katayama, N.; Yamanishi, K.; Nakanishi, K.; Mizutani, H. Granzyme B is a novel interleukin-18 converting enzyme. J. Dermatol. Sci., 2010, 59(2), 129-135.
84. Afonina, I. S.; Tynan, G. A.; Logue, S. E.; Cullen, S. P.; Bots, M.; Luthi, A. U.; Reeves, E. P.; McElvaney, N. G.; Medema, J. P.; Lavelle, E. C.; Martin, S. J. Granzyme B-Dependent Proteolysis Acts as a Switch to Enhance the Proinflammatory Activity of IL-1 alpha. Mol. Cell, 2011, 44(2), 265-278.
85. Sower, L. E.; Klimpel, G. R.; Hanna, W.; Froelich, C. J. Extracellular activities of human granzymes.1. Granzyme a induces IL6 and IL8 production in fibroblast and epithelial cell lines. Cell. Immunol., 1996, 171(1), 159-163.
86. Cooper, D. M.; Petchkovsky, D. V.; Hackett, T. L.; Knight, D. A.; Granville, D. J. Granzyme K Activates Protease-Activated Receptor-1. PLoS One, 2011, 6(6), e21484.
87. Wang, T. G.; Lee, M. H.; Choi, E.; Pardo-Villamizar, C. A.; Bin Lee, S.; Yang, I. H.; Calabresi, P. A.; Nath, A. Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel. PLoS One, 2012, 7(8), e43950.
88. Boivin, W. A.; Cooper, D. M.; Hiebert, P. R.; Granville, D. J. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab. Invest., 2009, 89(11), 1195-1220.
89. Rissoan, M. C.; Duhen, T.; Bridon, J. M.; Bendriss-Vermare, N.; Peronne, C.; de Saint Vis, B.; Briere, F.; Bates, E. E. M. Subtractive hybridization reveals the expression of immunoglobulinlike transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood, 2002, 100(9), 3295-3303.
90. Fehniger, T. A.; Cai, S. F.; Cao, X.; Bredemeyer, A. J.; Presti, R. I.; French, A. R.; Ley, T. J. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity, 2007, 26(6), 798-811.
91. Choy, J. C. Granzymes and perforin in solid organ transplant rejection. Cell Death Differ., 2010, 17(4), 567-576.
92. Freishtat, R. J.; Natale, J.; Benton, A. S.; Cohen, J.; Sharron, M.; Wiles, A. A.; Ngor, W. M.; Mojgani, B.; Bradbury, M.; Degnan, A.; Sachdeva, R.; DeBiase, L. M.; Ghimbovschi, S.; Chow, M.; Bunag, C.; Kristosturyan, E.; Hoffman, E. P. Sepsis Alters the Megakaryocyte-Platelet Transcriptional Axis Resulting in Granzyme B-mediated Lymphotoxicity. Am. J. Respir. Crit. Care Med., 2009, 179(6), 467-473.
93. Chaitanya, G. V.; Babu, P. P. Multiple apoptogenic proteins are involved in the nuclear translocation of Apoptosis Inducing Factor during transient focal cerebral ischemia in rat. Brain Res., 2008, 1246, 178-190.
94. Chaitanya, G. V.; Kolli, M.; Babu, P. P. Granzyme-b mediated cell death in the spinal cord-injured rat model. Neuropathology, 2009, 29(3), 270-279.
95. van den Wijngaard, R.; Wankowicz-Kalinska, A.; Le Poole, C.; Tigges, B.; Westerhof, W.; Das, P. Local immune response in skin of generalized vitiligo patients - Destruction of melanocytes is associated with the prominent presence of CLA (+) T cells at the perilesional site. Lab. Invest., 2000, 80(8), 1299-1309.
96. Thomas, H. E.; Trapani, J. A.; Kay, T. W. H. The role of perforin and granzymes in diabetes. Cell Death Differ., 2010, 17(4), 577-585.
97. Blanco, P.; Pitard, V.; Viallard, J. F.; Taupin, J. L.; Pellegrin, J. L.; Moreau, J. F. Increase in activated CD8+T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum., 2005, 52(1), 201-211.
98. Schachna, L.; Wigley, F. M.; Morris, S.; Gelber, A. C.; Rosen, A.; Casciola-Rosen, L. Recognition of granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum., 2002, 46(7), 1873-1884.
99. Cherin, P.; Herson, S.; Crevon, M. C.; Hauw, J. J.; Cervera, P.; Galanaud, P.; Emilie, D. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. J. Rheumatol., 1996, 23(7), 1135-1142.
100. Levine, S. M.; Raben, N.; Xie, D.; Askin, F. B.; Tuder, R.; Mullins, M.; Rosen, A.; Casciola-Rosen, L. A. Novel conformation of histidyl-transfer RNA synthetase in the lung - The target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum., 2007, 56(8), 2729-2739.
101. Froelich, C. J.; Zhang, X. L.; Turbov, J.; Hudig, D.; Winkler, U.; Hanna, W. L. Human Granzyme-B Degrades Aggrecan Proteoglycan in Matrix Synthesized by Chondrocytes. J. Immunol., 1993, 151(12), 7161-7171.
102. Buzza, M. S.; Zamurs, L.; Sun, J. R.; Bird, C. H.; Smith, A. I.; Trapani, J. A.; Froelich, C. J.; Nice, E. C.; Bird, P. I. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J. Biol. Chem., 2005, 280(25), 23549-23558.
103. Boivin, W. A.; Shackleford, M.; Vanden Hoek, A.; Zhao, H. Y.; Hackett, T. L.; Knight, D. A.; Granville, D. J. Granzyme B Cleaves Decorin, Biglycan and Soluble Betaglycan, Releasing Active Transforming Growth Factor-beta 1. PLoS One, 2012, 7, (3).
104. Tremblay, G. M.; Wolbink, A. M.; Cormier, Y.; Hack, C. E. Granzyme activity in the inflamed lung is not controlled by endogenous serine proteinase inhibitors. J. Immunol., 2000, 165(7), 3966-3969.
105. Kitamura, Y.; Hashimoto, S.; Mizuta, N.; Kobayashi, A.; Kooguchi, K.; Fujiwara, I.; Nakajima, H. Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice. Am. J. Respir. Crit. Care Med., 2001, 163(3), 762-769.
106. Miyazaki, H.; Kuwano, K.; Yoshida, K.; Maeyama, T.; Yoshimi, M.; Fujita, M.; Hagimoto, N.; Yoshida, R.; Nakanishi, Y. The perforin mediated apoptotic pathway in lung injury and fibrosis. J. Clin. Pathol., 2004, 57(12), 1292-1298.
107. Tschopp, C. M.; Spiegl, N.; Didichenko, S.; Lutmann, W.; Julius, P.; Virchow, J. C.; Hack, C. E.; Dahinden, C. A. Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma. Blood, 2006, 108(7), 2290-2299.
108. RensingEhl, A.; Malipiero, U.; Irmler, M.; Tschopp, J.; Constam, D.; Fontana, A. Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. Eur. J. Immunol., 1996, 26(9), 2271-2274.
109. Bien, C. G.; Bauer, J.; Deckwerth, T. L.; Wiendl, H.; Deckert, M.; Wiestler, O. D.; Schramm, J.; Elger, C. E.; Lassmann, H. Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in Rasmussen's encephalitis. Ann. Neurol., 2002, 51(3), 311-318.
110. Malmestrom, C.; Lycke, J.; Haghighi, S.; Andersen, O.; Carlsson, L.; Wadenvik, H.; Olsson, B. Relapses in multiple sclerosis are associated with increased CD8 (+) T-cell mediated cytotoxicity in CSF. J. Neuroimmunol., 2008, 196(1-2), 159-165.
111. Schwab, N.; Bien, C. G.; Waschbisch, A.; Becker, A.; Vince, G. H.; Dornmair, K.; Wiendl, H. CD8 T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain, 2009, 132, 1236-1246.
112. Saito, Y.; Kondo, H.; Hojo, Y. Granzyme B as a novel factor involved in cardiovascular diseases. J. Cardiol., 2011, 57(2), 141-147.
113. Tsuru, R.; Kondo, H.; Hojo, Y.; Gama, M.; Mizuno, O.; Katsuki, T.; Shimada, K.; Kikuchi, M.; Yashiro, T. Increased granzyme B production from peripheral blood mononuclear cells in patients with acute coronary syndrome. Heart, 2008, 94(3), 305-310.
114. Choy, J. C.; Hung, V. H. Y.; Hunter, A. L.; Cheung, P. K.; Motyka, B.; Goping, I. S.; Sawchuk, T.; Bleackley, R. C.; Podor, T. J.; McManus, B. M.; Granville, D. J. Granzyme B induces smooth muscle cell apoptosis in the absence of perforin - Involvement of extracellular matrix degradation. Arterioscler. Thromb. Vasc. Biol., 2004, 24(12), 2245-2250.
115. Tak, P. P.; Kummer, J. A.; Hack, C. E.; Daha, M. R.; Smeets, T. J. M.; Erkelens, G. W.; Meinders, A. E.; Kluin, P. M.; Breedveld, F. C. Granzyme-Positive Cytotoxic-Cells Are Specifically Increased in Early Rheumatoid Synovial Tissue. Arthritis Rheum., 1994, 3(12), 1735-1743.
116. Smeets, T. J. M.; Dolhain, R.; Breedveld, F. C.; Tak, P. P. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J. Pathol., 1998, 186(1), 75-81.
117. Kraan, M. C.; Haringman, J. J.; Weedon, H.; Barg, E. C.; Smith, M. D.; Ahern, M. J.; Smeets, T. J. M.; Breedveld, F. C.; Tak, P. P. T cells, fibroblast-like synoviocytes, and granzyme B plus cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis., 2004, 63(5), 483-488.
118. Ikemoto, T.; Hojo, Y.; Kondo, H.; Takahashi, N.; Hirose, M.; Nishimura, Y.; Katsuki, T.; Shimada, K. Plasma granzyme B as a predicting factor of coronary artery disease-Clinical significance in patients with chronic renal failure. J. Cardiol., 2009, 54(3), 409-415.
119. de Kruif, M. D.; Lemaire, L. C.; Giebelen, I. A.; Groot, A. P.; Pater, J. M.; van den Pangaart, P. S.; Elliott, P. J.; van der Poll, T. Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia. Shock, 2008, 29(4), 458-461.
120. Krukowski, K.; Eddy, J.; Kosik, K. L.; Konley, T.; Janusek, L. W.; Mathews, H. L. Glucocorticoid dysregulation of natural killer cell function through epigenetic modification. Brain Behav. Immun., 2011, 25(2), 239-249.
121. D'Eliseo, D.; Manzi, L.; Merendino, N.; Velotti, F. Docosahexaenoic acid inhibits invasion of human RT112 urinary bladder and PT45 pancreatic carcinoma cells via down-modulation of granzyme B expression. J. Nutr. Biochem., 2012, 23(5), 452-457.
122. Buzza, M. S.; Hirst, C. E.; Bird, C. H.; Hosking, P.; McKendrick, J.; Bird, P. I. The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses. Cell. Immunol., 2001, 210(1), 21-29.
123. Rowshani, A. T.; Strik, M. C. M.; Molenaar, R.; Yong, S. L.; Wolbink, A. M.; Bemelman, F. J.; Hack, C. E.; ten Berge, I. J. M. The granzyme B inhibitor SERPINB9 (protease inhibitor 9) circulates in blood and increases on primary cytomegalovirus infection after renal transplantation. J. Infect. Dis., 2005, 192(11), 1908-1911.
124. Kurschus, F. C.; Kleinschmidt, M.; Fellows, E.; Dornmair, K.; Rudolph, R.; Lilie, H.; Jenne, D. E. Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett., 2004, 562(1-3), 87-92.
125. Hendel, A.; Cooper, D.; Abraham, T.; Zhao, H. Y.; Allard, M. F.; Granville, D. J. Proteinase inhibitor 9 is reduced in human atherosclerotic lesion development. Cardiovasc. Pathol., 2012, 21(1), 28-38.
126. Kannan-Thulasiraman, P.; Shapiro, D. J. Modulators of inflammation use nuclear factor-B-K and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9. J. Biol. Chem., 2002, 277(43), 41230-41239.
127. Sun, J.; Whisstock, J. C.; Harriott, P.; Walker, B.; Novak, A.; Thompson, P. E.; Smith, A. I.; Bird, P. I. Importance of the P4' residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop. J. Biol. Chem., 2001, 276(18), 15177-15184.
128. Song, J. N.; Matthews, A. Y.; Reboul, C. F.; Kaiserman, D.; Pike, R. N.; Bird, P. I.; Whisstock, J. C. In Methods in Enzymology, Vol 501: Serpin Structure and Evolution; Elsevier Academic Press Inc: San Diego, 2011; Vol. 501, pp 237-273.
129. Poe, M.; Blake, J. T.; Boulton, D. A.; Gammon, M.; Sigal, N. H.; Wu, J. K.; Zweerink, H. J. Human Cytotoxic Lymphocyte Granzyme-B - Its Purification from Granules and the Characterization of Substrate and Inhibitor Specificity. J. Biol. Chem., 1991, 266(1), 98-103.
130. Sipione, S.; Simmen, K. C.; Lord, S. J.; Motyka, B.; Ewen, C.; Shostak, I.; Rayat, G. R.; Dufour, J. M.; Korbutt, G. S.; Rajotte, R. V.; Bleackley, R. C. Identification of a novel human granzyme B inhibitor secreted by cultured Sertoli cells. J. Immunol., 2006, 177(8), 5051-5058.
131. Ang, L. S.; Boivin, W. A.; Zhao, H. G.; Williams, S. J.; Varnals, T.; McManus, B. M.; Allard, M. F.; Bleackley, R. C.; Granville, D. J. Serpin A3N Reduces Abdominal Aortic Aneurysm Rupture in Mice by Inhibition of Extracellular Granzyme B. Arterioscler. Thromb. Vasc. Biol., 2010, 30(11), E235-E236.
132. Cullen, S. P.; Adrain, C.; Luthi, A. U.; Duriez, P. J.; Martin, S. J. Human and murine granzyme B exhibit divergent substrate preferences. J. Cell Biol., 2007, 176(4), 435-444.
133. El Haddad, N.; Heathcote, D.; Moore, R.; Yang, S. M.; Azzi, J.; Mfarrej, B.; Atkinson, M.; Sayegh, M. H.; Lee, J. S.; Ashton-Rickardt, P. G.; Abdi, R. Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood, 2011, 117(4), 1176-1183.
134. Raum, D.; Marcus, D.; Alper, C. A.; Levey, R.; Taylor, P. D.; Starzl, T. E. Synthesis of human plasminogen by the liver. Science, 1980, 208(4447), 1036-1037.
135. Schaller, J.; Gerber, S. S. The plasmin-antiplasmin system: structural and functional aspects. Cell. Mol. Life Sci., 2011, 68(5), 785-801.
136. Dano, K.; Andreasen, P. A.; Grondahl-Hansen, J.; Kristensen, P.; Nielsen, L. S.; Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 1985, 44, 139-266.
137. Tordai, H.; Banyai, L.; Patthy, L. The PAN module: the N-terminal domains of plasminogen and hepatocyte growth factor are homologous with the apple domains of the prekallikrein family and with a novel domain found in numerous nematode proteins. FEBS Lett., 1999, 461(1-2), 63-67.
138. Claeys, H.; Sottrup-Jensen, L.; Zajdel, M.; Petersen, T. E.; Magnusson, S. Multiple gene duplication in the evolution of plasminogen. Five regions of sequence homology with the two internally homologous structures in prothrombin. FEBS Lett., 1976, 61(1), 20-24.
139. Suenson, E.; Thorsen, S. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin. Biochem. J., 1981, 197(3), 619-628.
140. Wiman, B. Primary structure of the B-chain of human plasmin. Eur J. Biochem., 1977, 76(1), 129-137.
141. Weinstein, M. J.; Doolittle, R. F. Differential specificities of the thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors. Biochim. Biophys. Acta, 1972, 258(2), 577-590.
142. Mulichak, A. M.; Tulinsky, A.; Ravichandran, K. G. Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9-A resolution. Biochemistry, 1991, 30(43), 10576-10588.
143. Wu, T. P.; Padmanabhan, K. P.; Tulinsky, A. The structure of recombinant plasminogen kringle 1 and the fibrin binding site. Blood Coagul. Fibrinolysis, 1994, 5(2), 157-166.
144. Peisach, E.; Wang, J.; de los Santos, T.; Reich, E.; Ringe, D. Crystal structure of the proenzyme domain of plasminogen. Biochemistry, 1999, 38(34), 11180-11188.
145. Rios-Steiner, J. L.; Schenone, M.; Mochalkin, I.; Tulinsky, A.; Castellino, F. J. Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A Streptococcal surface protein. J. Mol. Biol., 2001, 308(4), 705-719.
146. Battistel, M. D.; Grishaev, A.; An, S. S.; Castellino, F. J.; Llinas, M. Solution structure and functional characterization of human plasminogen kringle 5. Biochemistry, 2009, 48(43), 10208-10219.
147. Christen, M. T.; Frank, P.; Schaller, J.; Llinas, M. Human plasminogen kringle 3: solution structure, functional insights, phylogenetic landscape. Biochemistry, 2010, 49(33), 7131-7150.
148. Bugge, T. H.; Flick, M. J.; Danton, M. J. S.; Daugherty, C. C.; Romer, J.; Dano, K.; Carmeliet, P.; Collen, D.; Degen, J. L. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA, 1996, 93(12), 5899-5904.
149. Feistritzer, C.; Sturn, D. H.; Kaneider, N. C.; Djanani, A.; Wiedermann, C. J. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J. Allergy Clin. Immunol., 2003, 112(2), 375-381.
150. Das, R.; Pluskota, E.; Plow, E. F. Plasminogen and Its Receptors as Regulators of Cardiovascular Inflammatory Responses. Trends Cardiovasc. Med., 2010, 20(4), 120-124.
151. Andronicos, N. M.; Chen, E. I.; Baik, N.; Bai, H.; Parmer, C. M.; Kiosses, W. B.; Kamps, M. P.; Yates, J. R., 3rd; Parmer, R. J.; Miles, L. A. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood, 2010, 115(7), 1319-1330.
152. Lighvani, S.; Baik, N.; Diggs, J. E.; Khaldoyanidi, S.; Parmer, R. J.; Miles, L. A. Regulation of macrophage migration by a novel plasminogen receptor Plg-R-KT. Blood, 2011, 118(20), 5622-5630.
153. Kim, S. O.; Plow, E. F.; Miles, L. A. Regulation of plasminogen receptor expression on monocytoid cells by beta (1)-integrindependent cellular adherence to extracellular matrix proteins. J. Biol. Chem., 1996, 271(39), 23761-23767.
154. Lerch, P. G.; Rickli, E. E.; Lergier, W.; Gillessen, D. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur. J. Biochem., 1980, 107(1), 7-13.
155. Aoki, N.; Moroi, M.; Tachiya, K. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin. Thromb. Haemost., 1978, 39(1), 22-31.
156. Walker, J. B.; Nesheim, M. E. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J. Biol. Chem., 1999, 274(8), 5201-5212.
157. Jennewein, C.; Tran, N.; Paulus, P.; Ellinghaus, P.; Eble, J. A.; Zacharowski, K. Novel aspects of fibrin (ogen) fragments during inflammation. Mol. Med., 2011, 17(5-6), 568-573.
158. Strickland, S.; Reich, E.; Sherman, M. I. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell, 1976, 9(2), 231-240.
159. Gross, J. L.; Moscatelli, D.; Rifkin, D. B. Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc. Natl. Acad. Sci. USA, 1983, 80(9), 2623-2627.
160. Schafer, B. M.; Maier, K.; Eickhoff, U.; Todd, R. F.; Kramer, M. D. Plasminogen activation in healing human wounds. Am. J. Pathol., 1994, 144(6), 1269-1280.
161. Ploplis, V. A.; French, E. L.; Carmeliet, P.; Collen, D.; Plow, E. F. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood, 1998, 91(6), 2005-2009.
162. Creemers, E.; Cleutjens, J.; Smits, J.; Heymans, S.; Moons, L.; Collen, D.; Daemen, M.; Carmeliet, P. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am. J. Pathol., 2000, 156(6), 1865-1873.
163. Levi, M.; Moons, L.; Bouche, A.; Shapiro, S. D.; Collen, D.; Carmeliet, P. Deficiency of urokinase-type plasminogen activatormediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation, 2001, 103(15), 2014-2020.
164. Oh, C. W.; Hoover-Plow, J.; Plow, E. F. The role of plasminogen in angiogenesis in vivo. J. Thromb. Haemost., 2003, 1(8), 1683-1687.
165. Saksela, O.; Rifkin, D. B. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell. Biol., 1988, 4, 93-126.
166. Nakagami, Y.; Abe, K.; Nishiyama, N.; Matsuki, N. Laminin degradation by plasmin regulates long-term potentiation. J. Neurosci., 2000, 20(5), 2003-2010.
167. Rabhi-Sabile, S.; de Romeuf, C.; Pidard, D. On the mechanism of plasmin-induced aggregation of human platelets: Implication of secreted von Willebrand factor. Thromb. Haemost., 1998, 79(6), 1191-1198.
168. Grabowska, M. M.; Day, M. L. Soluble E-cadherin: more than a symptom of disease. Front. Biosci., 2012, 17, 1948-1964.
169. Khalil, N.; Corne, S.; Whitman, C.; Yacyshyn, H. Plasmin regulates the activation of cell-associated latent TGF-beta (1) secreted by rat alveolar macrophages after in vivo bleomycin injury. Am. J. Respir. Cell Mol. Biol., 1996, 15(2), 252-259.
170. Godar, S.; Horejsi, V.; Weidle, U. H.; Binder, B. R.; Hansmann, C.; Stockinger, H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta 1. Eur. J. Immunol., 1999, 29(3), 1004-1013.
171. Wong, A. P.; Cortez, S. L.; Baricos, W. H. Role of plasmin and gelatinase in extracellular matrix degradation by cultured rat mesangial cells. Am. J. Physiol., 1992, 263 (6 Pt 2), F1112-1118.
172. Kassam, G.; Choi, K. S.; Ghuman, J.; Kang, H. M.; Fitzpatrick, S. L.; Zackson, T.; Zackson, S.; Toba, M.; Shinomiya, A.; Waisman, D. M. The role of annexin II tetramer in the activation of plasminogen. J. Biol. Chem., 1998, 273(8), 4790-4799.
173. Fitzpatrick, S. L.; Kassam, G.; Choi, K. S.; Kang, H. M.; Fogg, D. K.; Waisman, D. M. Regulation of plasmin activity by annexin II tetramer. Biochemistry, 2000, 39(5), 1021-1028.
174. Laumonnier, Y.; Syrovets, T.; Burysek, L.; Simmet, T. Identification of the annexin A2 heterotetramer as a receptor for the plasmininduced signaling in human peripheral monocytes. Blood, 2006, 107(8), 3342-3349.
175. Kamio, N.; Hashizume, H.; Nakao, S.; Matsushima, K.; Sugiya, H. Plasmin is involved in inflammation via protease-activated receptor-1 activation in human dental pulp. Biochem. Pharmacol., 2008, 75(10), 1974-1980.
176. Syrovets, T.; Lunov, O.; Simmet, T. Plasmin as a proinflammatory cell activator. J. Leukoc. Biol., 2012, 92(3), 509-519.
177. Jenkins, G. R.; Seiffert, D.; Parmer, R. J.; Miles, L. A. Regulation of plasminogen gene expression by interleukin-6. Blood, 1997, 89(7), 2394-2403.
178. Bannach, F. G.; Gutierrez, A.; Fowler, B. J.; Bugge, T. H.; Degen, J. L.; Parmer, R. J.; Miles, L. A. Localization of regulatory elements mediating constitutive and cytokine-stimulated plasminogen gene expression. J. Biol. Chem., 2002, 277(41), 38579-38588.
179. Abu-Mahfouz, M.; Cavalcante, J. L.; Arida, M.; Garcia, J.; Al-Mallah, M.; Boguszewski, A.; Haque, S.; Rehman, M.; Al Badarin, F.; Akhras, E.; Schultz, L.; Mitsias, P.; Alam, M.; Ananthasubramaniam, K. Significance of high sensitivity C-reactive protein and D-dimer in evaluating intracardiac thrombus and spontaneous echo contrast in patients referred for transesophageal echocardiography: A prospective study. Cardiol. J., 2012, 19(3), 267-273.
180. Wannamethee, S. G.; Whincup, P. H.; Lennon, L.; Rumley, A.; Lowe, G. D. Fibrin D-Dimer, Tissue-Type Plasminogen Activator, von Willebrand Factor, and Risk of Incident Stroke in Older Men. Stroke, 2012, 43(5), 1206-1211.
181. Hamaguchi, M.; Morishita, Y.; Takahashi, I.; Ogura, M.; Takamatsu, J.; Saito, H. FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line. Blood, 1991, 77(1), 94-100.
182. Thompson, W. D.; Smith, E. B.; Stirk, C. M.; Marshall, F. I.; Stout, A. J.; Kocchar, A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J. Pathol., 1992, 168(1), 47-53.
183. Bootle-Wilbraham, C. A.; Tazzyman, S.; Thompson, W. D.; Stirk, C. M.; Lewis, C. E. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis, 2001, 4(4), 269-275.
184. Naito, M.; Stirk, C. M.; Smith, E. B.; Thompson, W. D. Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis. Thromb. Res., 2000, 98(2), 165-174.
185. Lee, M. E.; Rhee, K. J.; Nham, S. U. Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages. Mol. Cells, 1999, 9(1), 7-13.
186. Lee, M. E.; Kweon, S. M.; Ha, K. S.; Nham, S. U. Fibrin stimulates microfilament reorganization and IL-1beta production in human monocytic THP-1 cells. Mol. Cells, 2001, 11(1), 13-20.
187. Bootle-Wilbraham, C. A.; Tazzyman, S.; Marshall, J. M.; Lewis, C. E. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res., 2000, 60(17), 4719-4724.
188. Krajewska, E.; Lewis, C. E.; Chen, Y. Y.; Welford, A.; Tazzyman, S.; Staton, C. A. A novel fragment derived from the beta chain of human fibrinogen, beta43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo. Br. J. Cancer, 2010, 102(3), 594-601.
189. Skogen, W. F.; Senior, R. M.; Griffin, G. L.; Wilner, G. D. Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood, 1988, 71(5), 1475-1479.
190. Lalla, R. V.; Tanzer, M. L.; Kreutzer, D. L. Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells. Arch. Oral. Biol., 2003, 48(4), 263-271.
191. Yakovlev, S.; Gao, Y.; Cao, C.; Chen, L.; Strickland, D. K.; Zhang, L.; Medved, L. Interaction of fibrin with VE-cadherin and antiinflammatory effect of fibrin-derived fragments. J. Thromb. Haemost., 2011, 9(9), 1847-1855.
192. Jennewein, C.; Mehring, M.; Tran, N.; Paulus, P.; Ockelmann, P. A.; Habeck, K.; Latsch, K.; Scheller, B.; Zacharowski, K.; Mutlak, H. The fibrinopeptide B beta 15-42 reduces inflammation in mice subjected to polymicrobial sepsis. Shock, 2012, 38(3), 275-280.
193. Petzelbauer, P.; Zacharowski, P. A.; Miyazaki, Y.; Friedl, P.; Wickenhauser, G.; Castellino, F. J.; Groger, M.; Wolff, K.; Zacharowski, K. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat. Med., 2005, 11(3), 298-304.
194. Sorensen, I.; Rong, S.; Susnik, N.; Gueler, F.; Shushakova, N.; Albrecht, M.; Dittrich, A. M.; von Vietinghoff, S.; Becker, J. U.; Melk, A.; Bohlmann, A.; Reingruber, S.; Petelbauer, P.; Haller, H.; Schmitt, R. B beta (15-42) Attenuates the Effect of Ischemia-Reperfusion Injury in Renal Transplantation. J. Am. Soc. Nephrol., 2011, 22(10), 1887-1896.
195. Atar, D.; Petzelbauer, P.; Schwitter, J.; Huber, K.; Rensing, B.; Kasprzak, J. D.; Butter, C.; Grip, L.; Hansen, P. R.; Suselbeck, T.; Clemmensen, P. M.; Marin-Galiano, M.; Geudelin, B.; Buser, P. T., Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F. I. R. E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J. Am. Coll. Cardiol., 2009, 53(8), 720-729.
196. Cesarman-Maus, G.; Hajjar, K. A., Molecular mechanisms of fibrinolysis. Br. J. Haematol., 2005, 129(3), 307-321.
197. Coleman, J. L.; Benach, J. L. Use of the plasminogen activation system by microorganisms. J. Lab. Clin. Med., 1999, 134(6), 567-576.
198. Hasumi, K.; Ohyama, S.; Kohyama, T.; Ohsaki, Y.; Takayasu, R.; Endo, A. Isolation of SMTP-3, 4, 5 and -6, novel analogs of staplabin, and their effects on plasminogen activation and fibrinolysis. J. Antibiot., 1998, 51(12), 1059-1068.
199. Hu, W. M.; Kitano, Y.; Hasumi, K. SMTP-4D, -5D, -6D, -7D and-8D, a new series of the non-lysine-analog plasminogen modulators with a D-amino acid moiety. J. Antibiot., 2003, 56(10), 832-837.
200. Guo, Y. Z.; Li, J. N.; Hagstrom, E.; Ny, T. Beneficial and Detrimental Effects of Plasmin (ogen) during Infection and Sepsis in Mice. PLoS One, 2011, 6(9), e24774.
201. Levi, M. The coagulant response in sepsis and inflammation. Hamostaseologie, 2010, 30(1), 10.
202. Renckens, R.; Weijer, S.; de Vos, A. F.; Pater, J. M.; Meijers, J. C.; Hack, C. E.; Levi, M.; van der Poll, T. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler. Thromb. Vasc. Biol., 2004, 24(3), 483-488.
203. Iba, T.; Kidokoro, A.; Fukunaga, M.; Sugiyama, K.; Sawada, T.; Kato, H. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock, 2005, 23(1), 25-29.
204. Schuster, V.; Mingers, A. M.; Seidenspinner, S.; Nussgens, Z.; Pukrop, T.; Kreth, H. W. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood, 1997, 90(3), 958-966.
205. Mingers, A. M.; Heimburger, N.; Zeitler, P.; Kreth, H. W.; Schuster, V. Homozygous type I plasminogen deficiency. Semin. Thromb. Hemost., 1997, 23(3), 259-269.
206. Drew, A. F.; Kaufman, A. H.; Kombrinck, K. W.; Danton, M. J. S.; Daugherty, C. C.; Degen, J. L.; Bugge, T. H. Ligneous conjunctivitis in plasminogen-deficient mice. Blood, 1998, 91(5), 1616-1624.
207. Schott, D.; Dempfle, C. E.; Beck, P.; Liermann, A.; Mohr-Pennert, A.; Goldner, M.; Mehlem, P.; Azuma, H.; Schuster, V.; Mingers, A. M.; Schwarz, H. P.; Kramer, M. D. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N. Engl. J. Med., 1998, 339(23), 1679-1686.
208. Li, J. N.; Ny, A.; Leonardsson, G.; Nandakumar, K. S.; Holmdahl, R.; Ny, T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am. J. Pathol., 2005, 166(3), 783-792.
209. Plow, E. F.; Hoover-Plow, J. The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med, 2004, 14(5), 180-186.
210. Brands-Nijenhuis, A. V.; van Geel, P. P.; Meijer, K. Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency. Blood Coagul. Fibrinolysis, 2009, 20(7), 599-600.
211. Syrovets, T.; Simmet, T. Novel aspects and new roles for the serine protease plasmin. Cell Mol. Life Sci., 2004, 61(7-8), 873-885.
212. Xiao, Q.; Danton, M. J.; Witte, D. P.; Kowala, M. C.; Valentine, M. T.; Bugge, T. H.; Degen, J. L. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc. Natl. Acad. Sci. USA, 1997, 94(19), 10335-10340.
213. Steins, M. B.; Padro, T.; Li, C. X.; Mesters, R. M.; Ostermann, H.; Hammel, D.; Scheld, H. H.; Berdel, W. E.; Kienast, J. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis, 1999, 145(1), 173-180.
214. Hashizume, H.; Kamio, N.; Nakao, S.; Matsushima, K.; Sugiya, H. Protein kinase C synergistically stimulates tumor necrosis factoralpha-induced secretion of urokinase-type plasminogen activator in human dental pulp cells. J. Physiol. Sci., 2008, 58(1), 83-86.
215. Ledesma, M. D.; Da Silva, J. S.; Crassaerts, K.; Delacourte, A.; De Strooper, B.; Dotti, C. G. Brain plasmin enhances APP alphacleavage and A beta degradation and is reduced in Alzheimer's disease brains. EMBO Rep., 2000, 1(6), 530-535.
216. Ledesma, M. D.; Abad-Rodriguez, J.; Galvan, C.; Biondi, E.; Navarro, P.; Delacourte, A.; Dingwall, C.; Dotti, C. G. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep., 2003, 4(12), 1190-1196.
217. Tucker, H. M.; Simpson, J.; Kihiko-Ehmann, M.; Younkin, L. H.; McGillis, J. P.; Younkin, S. G.; Degen, J. L.; Estus, S. Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. Neurosci. Lett., 2004, 368(3), 285-289.
218. Paul, J.; Strickland, S.; Melchor, J. P. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med., 2007, 204(8), 1999-2008.
219. Cortes-Canteli, M.; Paul, J.; Norris, E. H.; Bronstein, R.; Ahn, H. J.; Zamolodchikov, D.; Bhuvanendran, S.; Fenz, K. M.; Strickland, S. Fibrinogen and beta-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease. Neuron, 2010, 66(5), 695-709.
220. Zhang, Z. G.; Chopp, M.; Goussev, A.; Lu, D. Y.; Morris, D.; Tsang, W.; Powers, C.; Ho, K. L. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J. Neurosci., 1999, 19(24), 10898-10907.
221. Gabriel, C.; Ali, C.; Lesne, S.; Fernandez-Monreal, M.; Docagne, F.; Plawinski, L.; MacKenzie, E. T.; Buisson, A.; Vivien, D. Transforming growth factor alpha-induced expression of type-1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity. Faseb J., 2002, 16(14), 277.
222. Wiman, B.; Lijnen, H. R.; Collen, D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim. Biophys. Acta, 1979, 579(1), 142-154.
223. Frank, P. S.; Douglas, J. T.; Locher, M.; Llinas, M.; Schaller, J. Structural/functional characterization of the alpha 2-plasmin inhibitor C-terminal peptide. Biochemistry, 2003, 42(4), 1078-1085.
224. Wang, H.; Yu, A.; Wiman, B.; Pap, S. Identification of amino acids in antiplasmin involved in its noncovalent 'lysine-binding-site'-dependent interaction with plasmin. Eur. J. Biochem., 2003, 270(9), 2023-2029.
225. Miura, O.; Hirosawa, S.; Kato, A.; Aoki, N. Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. J. Clin. Invest., 1989, 83(5), 1598-1604.
226. Lind, B.; Thorsen, S. A novel missense mutation in the human plasmin inhibitor (alpha2-antiplasmin) gene associated with a bleeding tendency. Br. J. Haematol., 1999, 107(2), 317-322.
227. Blacker, D.; Wilcox, M. A.; Laird, N. M.; Rodes, L.; Horvath, S. M.; Go, R. C.; Perry, R.; Watson, B., Jr.; Bassett, S. S.; McInnis, M. G.; Albert, M. S.; Hyman, B. T.; Tanzi, R. E. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet., 1998, 19(4), 357-360.
228. Das, R.; Burke, T.; Plow, E. F. Histone H2B as a functionally important plasminogen receptor on macrophages. Blood, 2007, 110(10), 3763-3772.
229. Wygrecka, M.; Marsh, L. M.; Morty, R. E.; Henneke, I.; Guenther, A.; Lohmeyer, J.; Markart, P.; Preissner, K. T. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood, 2009, 113(22), 5588-5598.
230. Das, R.; Burke, T.; Van Wagoner, D. R.; Plow, E. F. L-Type Calcium Channel Blockers Exert an Antiinflammatory Effect by Suppressing Expression of Plasminogen Receptors on Macrophages. Circ. Res., 2009, 105(2), 167-U137.
231. Pollanen, J. Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids. J. Biol. Chem., 1989, 264(10), 5628-5632.
232. Felez, J.; Miles, L. A.; Plescia, J.; Plow, E. F. Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J. Cell. Biol., 1990, 111(4), 1673-1683.
233. Heinemann, V.; Ebert, M. P.; Laubender, R. P.; Bevan, P.; Mala, C.; Boeck, S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with nonresectable, locally advanced pancreatic cancer. Br. J. Cancer, 2013, 108(4), 766-770.
234. Swedberg, J. E.; Harris, J. M. Natural and Engineered Plasmin Inhibitors: Applications and Design Strategies. ChemBioChem, 2012, 13(3), 336-348.
235. Kesten, S.; Dehoyas, A.; Chaparro, C.; Westney, G.; Winton, T.; Maurer, J. R. Aprotinin Reduces Blood-Loss in Lung-Transplant Recipients. Ann. Thorac. Surg., 1995, 59(4), 877-879.
236. Capdevila, X.; Calvet, Y.; Biboulet, P.; Biron, C.; Rubenovitch, J.; d'Athis, F. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology, 1998, 88(1), 50-57.
237. Mangano, D. T.; Tudor, I. C.; Dietzel, C. The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med., 2006, 354(4), 353-365.
238. Fergusson, D. A.; Hebert, P. C.; Mazer, C. D.; Fremes, S.; MacAdams, C.; Murkin, J. M.; Teoh, K.; Duke, P. C.; Arellano, R.; Blajchman, M. A.; Bussieres, J. S.; Cote, D.; Karski, J.; Martineau, R.; Robblee, J. A.; Rodger, M.; Wells, G.; Clinch, J.; Pretorius, R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N. Engl. J. Med., 2008, 358(22), 2319-2331.
239. Sniecinski, R. M.; Karkouti, K.; Levy, J. H. Managing clotting: a North American perspective. Curr. Opin. Anesthesiol., 2012, 25(1), 74-79.
240. Murkin, J. M.; Falter, F.; Granton, J.; Young, B.; Burt, C.; Chu, M. High-Dose Tranexamic Acid Is Associated with Nonischemic Clinical Seizures in Cardiac Surgical Patients. Anesth. Analg., 2010, 110(2), 350-353.
241. Sander, M.; Spies, C. D.; Martiny, V.; Rosenthal, C.; Wernecke, K. D.; von Heymann, C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit. Care, 2010, 14(4), R148.
242. Markland, W.; Ley, A. C.; Lee, S. W.; Ladner, R. C. Iterative optimization of high-affinity protease inhibitors using phage display.1. Plasmin. Biochemistry, 1996, 35(24), 8045-8057.
243. Okada, Y.; Tsuda, Y.; Teno, N.; Wanaka, K.; Bohgaki, M.; Hijikataokunomiya, A.; Naito, T.; Okamoto, S. Synthesis of Active Center-Directed Peptide Inhibitors of Plasmin. Chem. Pharm. Bull., 1988, 36(4), 1289-1297.
244. Hervio, L. S.; Coombs, G. S.; Bergstrom, R. C.; Trivedi, K.; Corey, D. R.; Madison, E. L. Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. Chem. Biol., 2000, 7(6), 443-452.
245. Saupe, S. M.; Leubner, S.; Betz, M.; Klebe, G.; Steinmetzer, T. Development of new cyclic plasmin inhibitors with excellent potency and selectivity. J. Med. Chem., 2013, 56(3), 820-831.
246. Tang, J.; Yu, C. L.; Williams, S. R.; Springman, E.; Jeffery, D.; Sprengeler, P. A.; Estevez, A.; Sampang, J.; Shrader, W.; Spencer, J.; Young, W.; McGrath, M.; Katz, B. A. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J. Biol. Chem., 2005, 280(49), 41077-41089.
247. Mandle, R. J.; Colman, R. W.; Kaplan, A. P. Identification of Prekallikrein and High-Molecular-Weight Kininogen as a Complex in Human-Plasma. Proc. Natl. Acad. Sci. USA, 1976, 73(11), 4179-4183.
248. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem., 2002, 277(20), 17962-17969.
249. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood, 2004, 103(12), 4554-4561.
250. Plendl, J.; Snyman, C.; Naidoo, S.; Sawant, S.; Mahabeer, R.; Bhoola, K. D. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol. Chem., 2000, 381(11), 1103-1115.
251. Cassim, B.; Naidoo, S.; Naidoo, Y.; Williams, R.; Bhoola, K. D. Immunolocalisation of the kinin moiety and bradykinin (B2) receptors on synovial fluid neutrophils in rheumatoid arthritis. Immunopharmacology, 1996, 33(1-3), 321-324.
252. Bhoola, K. D.; Figueroa, C. D.; Worthy, K. Bioregulation of Kinins - Kallikreins, Kininogens, and Kininases. Pharmacol. Rev., 1992, 44(1), 1-80.
253. Zacest, R.; Oparil, S.; Talamo, R. C. Studies of Plasma Bradykininases Using Radiolabeled Substrates. Aus. J. Exp. Biol. Med. Sci., 1974, 52, 601-606.
254. Regoli, D. C.; Marceau, F.; Lavigne, J. Induction of B1-Receptors for Kinins in the Rabbit by a Bacterial Lipopolysaccharide. Eur. J. Pharmacol., 1981, 71, (1), 105-115.
255. Fernandes, E. S.; Passos, G. F.; Campos, M. M.; de Souza, G. E. P.; Fittipaldi, J. F.; Pesquero, J. L.; Teixeira, M. M.; Calixto, J. B. Cytokines and neutrophils as important mediators of platelet-activating factor-induced kinin B-1 receptor expression. Br. J. Pharmacol., 2005, 146(2), 209-216.
256. Gaginella, T. S.; Kachur, J. F. Kinins as Mediators of Intestinal Secretion. Am. J. Physiol., 1989, 256(1), G1-G15.
257. Houle, S.; Molinaro, G.; Adam, A.; Marceau, F. Tissue kallikrein actions at the rabbit natural or recombinant kinin B-2 receptors. Hypertension, 2003, 41(3), 611-617.
258. Hecquet, C.; Tan, F. L.; Marcic, B. M.; Erdos, E. G. Human bradykinin B-2 receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol., 2000, 58(4), 828-836.
259. Chao, J. L.; Yin, H.; Gao, L.; Hagiwara, M.; Shen, B.; Yang, Z. R.; Chao, L. Tissue kallikrein elicits cardioprotection by direct kinin B2 receptor activation independent of kinin formation. Hypertension, 2008, 52(4), 715-720.
260. Wang, C.; Chao, L.; Chao, J. Direct Gene Delivery of Human Tissue Kallikrein Reduces Blood-Pressure in Spontaneously Hypertensive Rats. J. Clin. Invest., 1995, 95(4), 1710-1716.
261. Xiong, W.; Chao, J.; Chao, L. Muscle Delivery of Human Kallikrein Gene Reduces Blood-Pressure in Hypertensive Rats. Hypertension, 1995, 25(4), 715-719.
262. Chao, J.; Shen, B.; Gao, L.; Xia, C. F.; Bledsoe, G.; Chao, L. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol. Chem., 2010, 391(4), 345-355.
263. Bernett, M. J.; Blaber, S. I.; Scarisbrick, I. A.; Dhanarajana, P.; Thomspon, S. M.; Blaber, M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem., 2002, 277(27), 24562-24570.
264. Laxmikanthan, G.; Blaber, S. I.; Bernett, M. J.; Scarisbrick, I. A.; Juliano, M. A.; Blaber, M. 1.70 angstrom X-ray structure of human apo kallikrein 1: Structural changes upon peptide inhibitor/substrate binding. Proteins, 2005, 58(4), 802-814.
265. Debela, M.; Magdolen, V.; Grimminger, V.; Sommerhoff, C.; Messerschmidt, A.; Huber, R.; Friedrich, R.; Bode, W.; Goettig, P. Crystal structures of human tissue kallikrein 4: Activity modulation by a specific zinc binding site. J. Mol. Biol., 2006, 362(5), 1094-1107.
266. Debela, M.; Hess, P.; Magdolen, V.; Schechter, N. M.; Steiner, T.; Huber, R.; Bode, W.; Goettig, P. Chymotryptic specificity determinants in the 1.0 angstrom structure of the zinc-inhibited human tissue kallikrein 7. Proc. Natl. Acad. Sci. USA, 2007, 104(41), 16086-16091.
267. Debela, M.; Goettig, P.; Magdolen, V.; Huber, R.; Schechter, N. M.; Bode, W. Structural basis of the zinc inhibition of human tissue kallikrein 5. J. Mol. Biol., 2007, 373(4), 1017-1031.
268. Yoon, H.; Laxmikanthan, G.; Lee, J.; Blaber, S. I.; Rodriguez, A.; Kogot, J. M.; Scarisbrick, I. A.; Blaber, M. Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J. Biol. Chem., 2007, 282(44), 31852-31864.
269. Magklara, A.; Mellati, A. A.; Wasney, G. A.; Little, S. P.; Sotiropoulou, G.; Becker, G. W.; Diamandis, E. P. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem. Biophys. Res. Commun., 2003, 307(4), 948-955.
270. Michael, I. P.; Pampalakis, G.; Mikolajczyk, S. D.; Malm, J.; Sotiropoulou, G.; Diamandis, E. P. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J Biol Chem, 2006, 281(18), 12743-12750.
271. Ishida-Yamamoto, A.; Kishibe, M. Involvement of corneodesmosome degradation and lamellar granule transportation in the desquamation process. Med. Mol. Morphol., 2011, 44(1), 1-6.
272. Brattsand, M.; Egelrud, T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem., 1999, 274, (42), 30033-30040.
273. Komatsu, N.; Saijoh, K.; Sidiropoulos, M.; Tsai, B.; Levesque, M. A.; Elliott, M. B.; Takehara, K.; Diamandis, E. P. Quantification of human tissue kallikreins in the stratum corneum: Dependence on age and gender. J. Invest. Dermatol., 2005, 125(6), 1182-1189.
274. Borgono, C. A.; Michael, I. P.; Komatsu, N.; Jayakumar, A.; Kapadia, R.; Clayman, G. L.; Sotiropoulou, G.; Diamandis, E. P. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem., 2007, 282(6), 3640-3652.
275. Simon, M.; Jonca, N.; Guerrin, M.; Haftek, M.; Bernard, D.; Caubet, C.; Egelrud, T.; Schmidt, R.; Serre, G. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J. Biol. Chem., 2001, 276(23), 20292-20299.
276. Caubet, C.; Jonca, N.; Brattsand, M.; Guerrin, M.; Bernard, D.; Schmidt, R.; Egelrud, T.; Simon, M.; Serre, G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol., 2004, 122(5), 1235-1244.
277. Descargues, P.; Deraison, C.; Prost, C.; Fraitag, S.; Mazereeuw-Hautier, J.; D'Alessio, M.; Ishida-Yamamoto, A.; Bodemer, C.; Zambruno, G.; Hovnanian, A. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsinlike hyperactivity in Netherton syndrome. J. Invest. Dermatol., 2006, 126(7), 1622-1632.
278. Ishida-Yamamoto, A.; Deraison, C.; Bonnart, C.; Bitoun, E.; Robinson, R.; O'Brien, T. J.; Wakamatsu, K.; Ohtsubo, S.; Takahashi, H.; Hashimoto, Y.; Dopping-Hepenstal, P. J. C.; McGrath, J. A.; Iizuka, H.; Richard, G.; Hovnanian, A. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J. Invest. Dermatol., 2005, 124(2), 360-366.
279. Komatsu, N.; Takata, M.; Otsuki, N.; Ohka, R.; Amano, O.; Takehara, K.; Saijoh, K. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol., 2002, 118(3), 436-443.
280. Yamasaki, K.; Schauber, J.; Coda, A.; Lin, H.; Dorschner, R. A.; Schechter, N. M.; Bonnart, C.; Descargues, P.; Hovnanian, A.; Gallo, R. L. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. Faseb J., 2006, 20(12), 2068-2080.
281. Murakami, M.; Ohtake, T.; Dorschner, R. A.; Schittek, B.; Garbe, C.; Gallo, R. L. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J. Invest. Dermatol., 2002, 119(5), 1090-1095.
282. Koczulla, R.; von Degenfeld, G.; Kupatt, C.; Krotz, F.; Zahler, S.; Gloe, T.; Issbrucker, K.; Unterberger, P.; Zaiou, M.; Lebherz, C.; Karl, A.; Raake, P.; Pfosser, A.; Boekstegers, P.; Welsch, U.; Hiemstra, P. S.; Vogelmeier, C.; Gallo, R. L.; Clauss, M.; Bals, R. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest., 2003, 111(11), 1665-1672.
283. Braff, M. H.; Zaiou, M.; Fierer, J.; Nizet, V.; Gallo, R. L. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect. Immun., 2005, 73(10), 6771-6781.
284. Shaw, J. L.; Petraki, C.; Watson, C.; Bocking, A.; Diamandis, E. P. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol. Chem., 2008, 389(12), 1513-1522.
285. Kumar, A.; Mikolajczyk, S. D.; Goel, A. S.; Millar, L. S.; Saedi, M. S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res., 1997, 57(15), 3111-3114.
286. Lovgren, J.; Rajakoski, K.; Karp, M.; Lundwall, a.; Lilja, H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun., 1997, 238(2), 549-555.
287. Takayama, T. K.; McMullen, B. A.; Nelson, P. S.; Matsumura, M.; Fujikawa, K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry, 2001, 40(50), 15341-15348.
288. Emami, N.; Diamandis, E. P. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. J. Biol. Chem., 2008, 283(6), 3031-3041.
289. Lovgren, J.; Airas, K.; Lilja, H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur. J. Biochem., 1999, 262(3), 781-789.
290. Malm, J.; Hellman, J.; Hogg, P.; Lilja, H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn (2+), a tight-binding inhibitor. Prostate, 2000, 45(2), 132-139.
291. Robert, M.; Gibbs, B. F.; Jacobson, E.; Gagnon, C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry, 1997, 36(13), 3811-3819.
292. Michael, I. P.; Sotiropoulou, G.; Pampalakis, G.; Magklara, A.; Ghosh, M.; Wasney, G.; Diamandis, E. P. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem., 2005, 280(15), 14628-14635.
293. Bourgeon, F.; Evrard, B.; Brillard-Bourdet, M.; Colleu, D.; Jegou, B.; Pineau, C. Involvement of semenogelin-derived peptides in the antibacterial activity of human seminal plasma. Biol. Reprod., 2004, 70(3), 768-774.
294. Edstrom, A. M.; Malm, J.; Frohm, B.; Martellini, J. A.; Giwercman, A.; Morgelin, M.; Cole, A. M.; Sorensen, O. E. The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins. J. Immunol., 2008, 181(5), 3413-3421.
295. Yao, C.; Karabasil, M. R.; Purwanti, N.; Li, X.; Akamatsu, T.; Kanamori, N.; Hosoi, K. Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice. J. Biol. Chem., 2006, 281(12), 7968-7976.
296. Nylander-Lundqvist, E.; Egelrud, T. Formation of active IL-1 beta from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm. Venereol., 1997, 77(3), 203-206.
297. Paliouras, M.; Diamandis, E. P. Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression. Tumour Biol., 2008, 29(2), 63-75.
298. Sotiropoulou, G.; Pampalakis, G. Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation. Biol. Chem., 2010, 391(4), 321-331.
299. Webber, M. M.; Waghray, A.; Bello, D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res., 1995, 1(10), 1089-1094.
300. Desrivieres, S.; Lu, H.; Peyri, N.; Soria, C.; Legrand, Y.; Menashi, S. Activation of the 92 kDa type IV collagenase by tissue kallikrein. J. Cell Physiol., 1993, 157(3), 587-593.
301. Menashi, S.; Fridman, R.; Desrivieres, S.; Lu, H.; Legrand, Y.; Soria, C. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann. NY Acad. Sci., 1994, 732, 466-468.
302. Devani, M.; Vecchi, M.; Ferrero, S.; Avesani, E. C.; Arizzi, C.; Chao, L.; Colman, R. W.; Cugno, M. Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation. Dig. Liver Dis., 2005, 37(9), 665-673.
303. Bertram, C. M.; Misso, N. L.; Fogel-Petrovic, M.; Figueroa, C. D.; Foster, P. S.; Thompson, P. J.; Bhoola, K. D. Expression of kinin receptors on eosinophils: comparison of asthmatic patients and healthy subjects. J. Leukoc. Biol., 2009, 85(3), 544-552.
304. Bhoola, K.; Ramsaroop, R.; Plendl, J.; Cassim, B.; Dlamini, Z.; Naicker, S. Kallikrein and kinin receptor expression in inflammation and cancer. Biol. Chem., 2001, 382(1), 77-89.
305. Bone, R. C.; Balk, R. A.; Cerra, F. B.; Dellinger, R. P.; Fein, A. M.; Knaus, W. A.; Schein, R. M.; Sibbald, W. J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992, 101(6), 1644-1655.
306. Kaplan, A. P.; Silverberg, M. The coagulation-kinin pathway of human plasma. Blood, 1987, 70(1), 1-15.
307. Laurindo, F. R.; Pedro Mde, A.; Barbeiro, H. V.; Pileggi, F.; Carvalho, M. H.; Augusto, O.; da Luz, P. L. Vascular free radical release. Ex vivo and in vivo evidence for a flow-dependent endothelial mechanism. Circ. Res., 1994, 74(4), 700-709.
308. Kaplan, A. P.; Reddigari, S.; Brunnee, T.; Nishikawa, K.; Kuna, P.; Silverberg, M. Studies of the activation and inhibition of the plasma kallikrein-kinin system. Agents Actions Suppl., 1992, 38 Pt 3), 317-328.
309. Whalley, E. T.; Solomon, J. A.; Modafferi, D. M.; Bonham, K. A.; Cheronis, J. C. CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl., 1992, 38 Pt 3), 413-420.
310. Melmon, K. L.; Webster, M. E.; Goldfinger, S. E.; Seegmiller, J. E. The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies. Arthritis Rheum., 1967, 10(1), 13-20.
311. Selwyn, B. M.; Figueroa, C. D.; Fink, E.; Swan, A.; Dieppe, P. A.; Bhoola, K. D. A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis. Ann. Rheum. Dis., 1989, 48(2), 128-133.
312. Rahman, M. M.; Worthy, K.; Elson, C. J.; Fink, E.; Dieppe, P. A.; Bhoola, K. D. Inhibitor regulation of tissue kallikrein activity in the synovial fluid of patients with rheumatoid arthritis. Br. J. Rheumatol., 1994, 33(3), 215-223.
313. Rahman, M. M.; Lemon, M. J.; Elson, C. J.; Dieppe, P. A.; Bhoola, K. D. Proinflammatory role of tissue kallikrein in modulating pain in inflamed joints. Br. J. Rheumatol., 1995, 34, (1), 88-90.
314. Isordia-Salas, I.; Pixley, R. A.; Sainz, I. M.; Martinez-Murillo, C.; Colman, R. W. The role of plasma high molecular weight kininogen in experimental intestinal and systemic inflammation. Arch. Med. Res., 2005, 36(1), 87-95.
315. Cassim, B.; Naidoo, S.; Ramsaroop, R.; Bhoola, K. D. Immunolocalization of bradykinin receptors on human synovial tissue. Immunopharmacology, 1997, 36(2-3), 121-125.
316. Dela Cadena, R. A.; Stadnicki, A.; Uknis, A. B.; Sartor, R. B.; Kettner, C. A.; Adam, A.; Colman, R. W. Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat. Faseb J., 1995, 9(5), 446-452.
317. Sharma, J. N.; Ishak, F. I.; Yusof, A. P. M.; Srivastava, K. C. Effects of eugenol and ginger oil on adjuvant arthritis and the kallikreins in rats. Asia Pac. J. Pharmacol., 1997, 12(1-2), 9-14.
318. Valenti, C.; Giuliani, S.; Cialdai, C.; Tramontana, M.; Maggi, C. A. Fasitibant chloride, a kinin B2 receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br. J. Pharmacol., 2012, 166(4), 1403-1410.
319. Valenti, C.; Giuliani, S.; Cialdai, C.; Tramontana, M.; Maggi, C. A. Anti-inflammatory synergy of MEN16132, a kinin B-2 receptor antagonist, and dexamethasone in carrageenan-induced knee joint arthritis in rats. Br. J. Pharmacol., 2010, 161(7), 1616-1627.
320. Yamasaki, K.; Gallo, R. L. Rosacea as a disease of cathelicidins and skin innate immunity. J. Investig. Dermatol. Symp. Proc., 2011, 15(1), 12-15.
321. Yamasaki, K.; Di Nardo, A.; Bardan, A.; Murakami, M.; Ohtake, T.; Coda, A.; Dorschner, R. A.; Bonnart, C.; Descargues, P.; Hovnanian, A.; Morhenn, V. B.; Gallo, R. L. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med., 2007, 13(8), 975-980.
322. Komatsu, N.; Saijoh, K.; Kuk, C.; Shirasaki, F.; Takehara, K.; Diamandis, E. P. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br. J. Dermatol., 2007, 156(5), 875-883.
323. Lande, R.; Gregorio, J.; Facchinetti, V.; Chatterjee, B.; Wang, Y. H.; Homey, B.; Cao, W.; Wang, Y. H.; Su, B.; Nestle, F. O.; Zal, T.; Mellman, I.; Schroder, J. M.; Liu, Y. J.; Gilliet, M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007, 449(7162), 564-569.
324. Chavanas, S.; Bodemer, C.; Rochat, A.; Hamel-Teillac, D.; Ali, M.; Irvine, A. D.; Bonafe, J. L.; Wilkinson, J.; Taieb, A.; Barrandon, Y.; Harper, J. I.; de Prost, Y.; Hovnanian, A. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet., 2000, 25(2), 141-142.
325. Sprecher, E.; Chavanas, S.; Di Giovanna, J. J.; Amin, S.; Nielsen, K.; Prendiville, J. S.; Silverman, R.; Esterly, N. B.; Spraker, M. K.; Guelig, E.; de Luna, M. L.; Williams, M. L.; Buehler, B.; Siegfried, E. C.; Van Maldergem, L.; Pfendner, E.; Bale, S. J.; Uitto, J.; Hovnanian, A.; Richard, G. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J. Invest. Dermatol., 2001, 117(2), 179-187.
326. Hachem, J. P.; Wagberg, F.; Schmuth, M.; Crumrine, D.; Lissens, W.; Jayakumar, A.; Houben, E.; Mauro, T. M.; Leonardsson, G.; Brattsand, M.; Egelrud, T.; Roseeuw, D.; Clayman, G. L.; Feingold, K. R.; Williams, M. L.; Elias, P. M. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol., 2006, 126(7), 1609-1621.
327. Diamandis, E. P.; Yousef, G. M.; Soosaipillai, A. R.; Grass, L.; Porter, A.; Little, S.; Sotiropoulou, G. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin. Biochem., 2000, 33(5), 369-375.
328. Shaw, J. L.; Diamandis, E. P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem., 2007, 53(8), 1423-1432.
329. Bando, Y.; Ito, S.; Nagai, Y.; Terayama, R.; Kishibe, M.; Jiang, Y. P.; Mitrovic, B.; Takahashi, T.; Yoshida, S. Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci. Lett., 2006, 405(3), 175-180.
330. Scarisbrick, I. A.; Linbo, R.; Vandell, A. G.; Keegan, M.; Blaber, S. I.; Blaber, M.; Sneve, D.; Lucchinetti, C. F.; Rodriguez, M.; Diamandis, E. P. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem., 2008, 389(6), 739-745.
331. Scarisbrick, I. A.; Blaber, S. I.; Lucchinetti, C. F.; Genain, C. P.; Blaber, M.; Rodriguez, M. Activity of a newly identified serine protease in CNS demyelination. Brain, 2002, 125 Pt 6), 1283-1296.
332. Angelo, P. F.; Lima, A. R.; Alves, F. M.; Blaber, S. I.; Scarisbrick, I. A.; Blaber, M.; Juliano, L.; Juliano, M. A. Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J. Biol. Chem., 2006, 281(6), 3116-3126.
333. Blaber, S. I.; Scarisbrick, I. A.; Bernett, M. J.; Dhanarajan, P.; Seavy, M. A.; Jin, Y.; Schwartz, M. A.; Rodriguez, M.; Blaber, M. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry, 2002, 41(4), 1165-1173.
334. Christophi, G. P.; Isackson, P. J.; Blaber, S.; Blaber, M.; Rodriguez, M.; Scarisbrick, I. A. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J. Neurochem., 2004, 91(6), 1439-1449.
335. Blaber, S. I.; Ciric, B.; Christophi, G. P.; Bernett, M. J.; Blaber, M.; Rodriguez, M.; Scarisbrick, I. A. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. Faseb J., 2004, 18(7), 920-922.
336. Vandell, A. G.; Larson, N.; Laxmikanthan, G.; Panos, M.; Blaber, S. I.; Blaber, M.; Scarisbrick, I. A. Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J. Neurochem., 2008, 107(3), 855-870.
337. Tsuda, Y.; Teno, N.; Okada, Y.; Wanaka, K.; Bohgaki, M.; Hijikataokunomiya, A.; Okamoto, U.; Naito, T.; Okamoto, S. Synthesis of Tripeptide Chloromethyl Ketones and Examination of Their Inhibitory Effects on Plasmin and Plasma Kallikrein. Chem. Pharm. Bull., 1989, 37(11), 3108-3111.
338. Ghazi, A.; Grant, J. A. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics, 2013, 7, 103-113.
339. Geiger, R.; Stuckstedte, U.; Clausnitzer, B.; Fritz, H. Progressive Inhibition of Human Glandular (Urinary) Kallikrein by Human-Serum and Identification of the Progressive Anti-Kallikrein as Alpha-1-Antitrypsin (Alpha-1-Protease Inhibitor. Hoppe-Seylers Zeitschrift Fur Physiologische Chemie, 1981, 362(3), 317-325.
340. Zhou, G. X.; Chao, L.; Chao, J. Kallistatin - a Novel Human Tissue Kallikrein Inhibitor - Purification, Characterization, and Reactive Center Sequence. J. Biol. Chem., 1992, 267(36), 25873-25880.
341. Chao, J. L.; Schmaier, A.; Chen, L. M.; Yang, Z. R.; Chao, L. Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease. J. Lab. Clin. Med., 1996, 127(6), 612-620.
342. Chao, J.; Chai, K. X.; Chao, L. Tissue kallikrein inhibitors in mammals. Immunopharmacology, 1996, 32(1-3), 67-72.
343. Deraison, C.; Bonnart, C.; Lopez, F.; Besson, C.; Robinson, R.; Jayakumar, A.; Wagberg, F.; Brattsand, M.; Hachem, J. P.; Leonardsson, G.; Hovnanian, A. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell, 2007, 18, (9), 3607-3619.
344. Schneider, L. A.; Korber, A.; Grabbe, S.; Dissemond, J. Influence of pH on wound-healing: a new perspective for wound-therapy? Arch. Dermatol. Res., 2007, 298(9), 413-420.
345. Lundwall, A.; Brattsand, M. Kallikrein-related peptidases. Cell Mol. Life Sci., 2008, 65(13), 2019-2038.
346. Schechter, N. M.; Choi, E. J.; Wang, Z. M.; Hanakawa, Y.; Stanley, J. R.; Kang, Y.; Clayman, G. L.; Jayakumar, A. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lymphoepithelial Kazal-type inhibitor (LEKTI). Biol. Chem., 2005, 386(11), 1173-1184.
347. Magert, H. J.; Standker, L.; Kreutzmann, P.; Zucht, H. D.; Reinecke, M.; Sommerhoff, C. P.; Fritz, H.; Forssmann, W. G. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J. Biol. Chem., 1999, 274(31), 21499-21502.
348. Magert, H. J.; Kreutzmann, P.; Standker, L.; Walden, M.; Drogemuller, K.; Forssmann, W. G. LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance. Int. J. Biochem. Cell Biol., 2002, 34(6), 573-576.
349. Vasileiou, Z.; Barlos, K. K.; Gatos, D.; Adermann, K.; Deraison, C.; Barlos, K. Synthesis of the Proteinase Inhibitor LEKTI Domain 6 by the Fragment Condensation Method and Regioselective Disulfide Bond Formation. Biopolymers, 2010, 94(3), 339-349.
350. Franzke, C. W.; Baici, A.; Bartels, J.; Christophers, E.; Wiedow, O. Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J. Biol. Chem., 1996, 271(36), 21886-21890.
351. Galliano, M. F.; Toulza, E.; Gallinaro, H.; Jonca, N.; Ishida-Yamamoto, A.; Serre, G.; Guerrin, M. A novel protease inhibitor of the alpha2-macroglobulin family expressed in the human epidermis. J. Biol. Chem., 2006, 281(9), 5780-5789.
352. Costello, L. C.; Feng, P.; Milon, B.; Tan, M.; Franklin, R. B. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis., 2004, 7(2), 111-117.
353. Hsieh, M. C.; Cooperman, B. S. The preparation and catalytic properties of recombinant human prostate-specific antigen (rPSA). Biochim. Biophys. Acta, 2000, 1481(1), 75-87.
354. Jonsson, M.; Linse, S.; Frohm, B.; Lundwall, A.; Malm, J. Semenogelins I and II bind zinc and regulate the activity of prostatespecific antigen. Biochem J, 2005, 387 Pt 2), 447-453.
355. Sotiropoulou, G.; Pampalakis, G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol. Sci., 2012, 33(12), 623-634.
356. Acheampong, P.; Ford, G. A. Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin. Drug Metab. Toxicol., 2012, 8(2), 271-281.
357. Tapson, V. F. Thrombolytic therapy for acute pulmonary embolism. Semin. Thromb. Hemost., 2013, 39(4), 452-458.
358. Rawlings, N. D.; Barrett, A. J.; Bateman, A. MEROPS: the peptidase database. Nucleic Acids Res., 2010, 38, D227-D233.